{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:45Z","timestamp":1788174585984,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","award":["P30 CA043703"],"award-info":[{"award-number":["P30 CA043703"]}],"id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41375-023-01915-y","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:06:34Z","timestamp":1684865194000},"page":"1558-1560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-2640","authenticated-orcid":false,"given":"Akiva","family":"Diamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyatt P.","family":"Bensken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran M.","family":"Koroukian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"1915_CR1","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"1915_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2019-122516","volume":"134","author":"AJ Olszewski","year":"2019","unstructured":"Olszewski AJ, Davids MS, Yakirevich I, Egan PC. Early adoption and outcomes of ibrutinib as treatment for older patients with chronic lymphocytic leukemia (CLL): a population-based study. Abstracts from 2019 American Society of Hematology (ASH) Annual Meeting. Blood. 2019;134:265.","journal-title":"Blood."},{"key":"1915_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1056\/NEJMc1600328","volume":"374","author":"JP Sharman","year":"2016","unstructured":"Sharman JP, Mato AR, Keating MJ. Ibrutinib for chronic lymphocytic leukemia. N Engl J Med. 2016;374:1592\u20133.","journal-title":"N Engl J Med"},{"key":"1915_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evidence"},{"key":"1915_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontology Ser A. 2018;73:980\u20137.","journal-title":"J Gerontology Ser A."},{"key":"1915_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jgo.2022.06.011","volume":"13","author":"WP Bensken","year":"2022","unstructured":"Bensken WP, Schiltz NK, Warner DF, Kim DH, Wei MY, Qui\u00f1ones AR, et al. Comparing the association between multiple chronic conditions, multimorbidity, frailty, and survival among older cancer patients. J Geriatr Oncol. 2022;13:1244\u201352.","journal-title":"J Geriatr Oncol."},{"key":"1915_CR7","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R, B\u00f6ttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209\u201316.","journal-title":"J Clin Oncol"},{"key":"1915_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. New England J Med. 2018;379:2517\u201328.","journal-title":"New England J Med"},{"key":"1915_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01915-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01915-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T14:03:54Z","timestamp":1688393034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01915-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01915-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AD, WB, WD, LV do not have relevant conflicts to report. In the past 36 months, WB, LV, and SMK were supported by grants from the National Cancer Institute, Case Comprehensive Cancer Center (P30 CA043703); SMK was also supported by a grant from the American Cancer Society (132678-RSGI-19-213-01-CPHPS), and by contracts from Cleveland Clinic Foundation, including a subcontract from Celgene Corporation. Additional sources of support for Dr. Koroukian include grants from the National Institutes of Health (R15 NR017792, and UH3-DE025487) and the American Cancer Society (RWIA-20-111-02 RWIA). PFC reports grants from ADC Therapeutics SA and Genentech, consulting fees from Genentech, ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetics, Amgen, TG Therapeutics, Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}